Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the currently recommended treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). Acquired resistance inevitably develops, with the EGFR T790M mutation comprising approximately 55% of the mechanisms...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ther Adv Med Oncol
Hlavní autoři: Liao, Bin-Chi, Griesing, Sebastian, Yang, James Chih-Hsin
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2019
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6878608/
https://ncbi.nlm.nih.gov/pubmed/31803256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919890286
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky